The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

Frank Torti, président et président du conseil Vant, a vendu le 19 février 2026 un total de 3 000 000 d'actions de Roivant Sciences pour un montant de 82 039 460 $. Suite au dépôt ...

L’action de Roivant Sciences Ltd a atteint un sommet historique de 27,95$, marquant une étape importante pour cette société biopharmaceutique. L’action se négocie à seulement 1% en dessous de son plus ...

WASHINGTON, DC – When billionaires are in the spotlight for their oversized influence in Washington, especially in the Trump administration, comes this news: Vivek Ramaswamy’s wealth has soared even ...

Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating.

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising ...

Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...